Cidara Therapeutics, Inc. announced on February 18, 2025, the appointment of Frank Karbe, MBA, as its new Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing the company.
Mr. Karbe brings over 25 years of leadership experience in life sciences, healthcare, and technology, including roles as CEO and President of Better Therapeutics and President and CFO of Myovant Sciences. At Myovant, he was instrumental in scaling the company, raising over $2 billion in capital, and securing a $4 billion partnership with Pfizer.
This appointment is significant as Cidara advances its lead influenza antiviral drug, CD388, through late-stage clinical development and plans for Phase 3 and beyond. Mr. Karbe's proven track record in transitioning companies to multi-billion-dollar commercial organizations is expected to be invaluable to Cidara's strategic vision and growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.